Home Diversity-oriented synthesis of amide derivatives of tricyclic thieno[2,3-d]pyrimidin-4(3H)-ones and evaluation of their influence on melanin synthesis in murine B16 cells
Article Open Access

Diversity-oriented synthesis of amide derivatives of tricyclic thieno[2,3-d]pyrimidin-4(3H)-ones and evaluation of their influence on melanin synthesis in murine B16 cells

An erratum for this article can be found here: https://doi.org/10.1515/hc-2018-2002
  • Li Fei Nie , Guozheng Huang ORCID logo , Khurshed Bozorov ORCID logo , Jiangyu Zhao , Chao Niu , Shamansur S. Sagdullaev and Haji A. Aisa EMAIL logo
Published/Copyright: January 25, 2018

Abstract

A diversity-oriented synthesis of amide-containing thieno[2,3-d]pyrimidin-4(3H)-ones is reported. All compounds were tested for their influence on melanin synthesis in murine B16 cells. The azepine fragment in thieno[2,3-d]pyrimidin-4(3H)-one skeleton significantly increases the melanin content.

Introduction

Vitiligo is a disease characterized by loss of pigment cells in the epidermis [1]. It can involve any part of the body where melanocytes reside and cause both functional and physiological abnormalities in the affected skin. So far, several theories have been generated to explain the pathogenesis of the vitiligo disease [2]. It is generally believed that the disease results from the destruction of melanocytes and obstruction of the melanin synthesis [3].

Presently, there are several drugs used for the treatment of vitiligo including topical corticosteroids, calcineurin inhibitors, vitamin D3 analogs and psoralens [4]. Several psoralens (furocoumarins) have been clinically applied, including 8-methoxypsoralen (8-MOP, Figure 1) [5], [6], 5-methoxypsoralen [7] and 4,5,8-trimethylpsoralen [8], [9]. These compounds show strong photosensitivity, which may be used for the treatment of vitiligo with subsequent exposure to long-wave ultraviolet (UV) radiation. Nowadays, this therapy is still the most successful approach for the treatment of vitiligo, although there are some undesired side effects such as genetic mutation and risk of skin cancer [10], [11]. In order to discover new active drug candidates, our group has synthesized dozens of psoralen derivatives. In vitro evaluation has indicated that some of them possess good stimulation effects on tyrosinase and melanin synthesis in murine B16 cells [12], [13].

Figure 1 Structures of 8-methoxypsolaren (8-MOP) and related derivatives of thieno[2,3-d]pyrimidin-4(3H)-one [5].
Figure 1

Structures of 8-methoxypsolaren (8-MOP) and related derivatives of thieno[2,3-d]pyrimidin-4(3H)-one [5].

Thieno[2,3-d]pyrimidin-4(3H)-one is a common building block for drugs with diverse pharmaceutical activities [14], [15], [16]. It has been widely used for the preparation of new antibacterial [17], [18] and antitumor agents [19], among other drugs. As can be seen from Figure 1, the core of thieno[2,3-d]pyrimidin-4(3H)-one is similar to that of psoralen, and we envisioned that derivatives of thieno[2,3-d]pyrimidin-4(3H)-one might function similarly to psoralen derivatives. Recently, 18 new sulfonamides derived from 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidin-4-one have been synthesized by our group. Several compounds exhibited more than 1.5-fold potency as compared to 8-MOP [5]. In the present study, inspired by these positive results, we synthesized 51 novel amide derivatives of tricyclic thieno[2,3-d]pyrimidines and investigated their activities on melanin synthesis in murine B16 cells.

Results and discussion

Synthesis

The synthetic route of the target compounds (Scheme 1) follows our previous procedure [5]. An intermediate product 1 was prepared from diethyl oxalate via the Grignard reaction. Application of the Gewald reaction to compound 1, cyanoacetate and sulfur in the presence of triethylamine at room temperature produced compound 2 in high yield. Then, ethyl thieno[2,3-d]pyrimidine carboxylates 3–5 were prepared through the condensation of compound 2 and cyclic lactams in the presence of phosphorus oxychloride in dichloromethane at 45°C. Hydrolysis of esters 3–5 was completed in a mixture of water and methanol in the presence of lithium hydroxide to yield the acids 6–8. In order to obtain the amidation products in good yields, the optimization reactions with acid 6 under different conditions using a mixture of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and hydroxybenzotriazole (EDCI and HOBt), (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) and oxalyl chloride as activating reagents were conducted. n-Butylamine and 1-(4-aminophenyl)ethan-1-one were selected to represent aliphatic and aromatic amines, respectively. Using the coupling reagents EDCI and HOBt, the yields were only moderate for both aliphatic amine (53%) and aromatic amine (65%). HATU provided a good yield for the reaction of aliphatic amine (88%), slightly better than for aromatic amine (74%). the conversion of acid 6 to carboxylic chloride and then condensation with amine provided excellent yields with the aromatic amine (90%), much better than for the aliphatic n-butylamine. Therefore, it was decided to synthesize the target compounds 9a–e, 10a–e, 11a–e bearing the aliphatic amino moiety in the presence of HATU and to prepare compounds 9f–q, 10f–q, 11f–q with aromatic amine moiety from carboxylic acid chloride.

Scheme 1 Synthetic route to compounds 9a–q, 10a–q and 11a–q.
Scheme 1

Synthetic route to compounds 9a–q, 10a–q and 11a–q.

Melanin synthesis evaluation

All the tricyclic thieno[2,3-d]pyrimidin-4(3H)-one derivatives 9a–q, 10a–q, 11a–q were tested for their effect on melanin synthesis in murine B16 cells, following a previously published method [20]. As shown in Table 1, the reference drug 8-MOP enhances the melanin synthesis by 126.1±3.2% at 50 μm as compared to the blank control. The effectiveness of the synthetic compounds on melanin synthesis varies from 40.6±11.4 to 234.5±5.9%. It can be noticed that the five-membered ring compounds (9a–q, n=1) showed decreased melanin synthesis, no matter what kind of substituent group is present on the amide moiety. Among these 17 compounds, only compounds 9d and 9i showed higher values than 8-MOP. Several compounds fused with a seven-membered ring (11, n=3) possess better activities to promote melanin content. Some six-membered derivatives (10, n=2) show high potency. Most of them (11 out of 17) increase the synthesis of melanin. It can be concluded that the size of fused rings of the synthetic compounds dramatically affects their ability to influence melanin synthesis.

Table 1

Stimulation of melanin content of B16 cells by compounds 9a–q, 10a–q, 11a–q.

CompoundRelative melain contents (%)CompoundRelative melain contents (%)CompoundRelative melain contents (%)
9a87.2±2.510a109.1±9.911a97.1±3.2
9b125.6±3.410b105.9±1.411b155.8±5.6
9c126.4±5.510c133.2±1.811c161.7±7.1
9d151.4±6.410d174.5±4.711d111.5±9.8
9e125.6±3.410e159.6±5.111e49.1±7.6
9f85.5±6.910f151.9±5.211f143.9±6.3
9g88.5±7.810g103.0±6.811g173.4±10.8
9h103.5±5.210h227.6±4.311h82.9±13.1
9i147.1±2.610i112.5±7.811i116.6±3.7
9j122.5±7.110j126.4±9.511j92.5±10.9
9k96.1±8.410k187.9±8.611k105.3±6.1
9l116.6±6.810l155.8±7.911l147.0±4.3
9m114.7±4.910m201.2±6.711m136.7±8.2
9n113.1±5.610n154.4±5.611n234.5±5.9
9o116.9±7.110o130.7±6.211o94.5±10.7
9p114.6±7.610p154.4 ±8 .611p150.4±4.6
9q75.1±4.610q95.4±3.911q40.6±11.4
8-MOP126.1±3.2
  1. The data were recorded as the mean±SD% of three experiments in duplicate and compared to the blank control.

Substituents on the amide moiety also contribute to the biological effectiveness. For example, compounds with n-octylamino group 9d, 10d, 11d exhibit an increased potency in comparison to the derivatives substituted with an n-butylamino group 9a, 10a, 11a. Compound 11n is the lead candidate showing the highest potency on melanin synthesis in murine B16 cells, with a value of 234.5±5.9%, which is 1.86-fold greater compared to that of 8-MOP. Another hit compound is 10h which contains electron-donating substituent (methoxy group) attached to position 4 of the aromatic ring and increases the melanin content by 227.6±4.3%. Interestingly, activities of compounds with a 2,6-dichlorophenyl fragment in amide linker increase with the increase in size of the saturated ring 9n<10n<11n.

Conclusion

New amide-substituted tricyclic thieno[2,3-d]pyrimidin-4(3H)-one derivatives were synthesized and evaluated for their effect on melanin synthesis in murine B16 cells. Several synthetic compounds are more potent than the standard drug 8-methoxypsolaren.

Experimental

Reagents and solvents were purchased from Sigma and used without purification. Thin-layer chromatography (TLC) was carried out on glass plates coated with silica gel (Qingdao Haiyang Chemical Co., G60F-254); spots were visualized by illumination with UV light (254 nm). The products were purified by column chromatography over silica gel (Qingdao Haiyang Chemical Co., 200–300 mesh). Melting points were determined on a Buchi B-540 apparatus and are uncorrected. Proton nuclear magnetic resonance (1H NMR), (400 MHz) and carbon-13 nuclear magnetic resonance (13C NMR) (100 MHz) spectra were recorded on a Varian NMR spectrometer in deuterated chloroform (CDCl3) using tetramethylsilane (TMS) as an internal standard. High-resolution mass spectra (HRMS) were recorded on an AB SCIEX QSTAR Elite quadrupole time-of-flight mass spectrometer.

General procedure for the synthesis of compounds 9a–q, 10a–q and 11a–q

Method A To a solution of 2-methyl-4-oxo-thieno[2,3-d]pyrimidine-3-carboxylic acid (6–8, 1.0 mmol) and HATU (1.2 mmol) in dichloromethane (20 mL) was added N,N-diisopropylethylamine (DIPEA, 0.27 mL, 1.5 mmol) and an aliphatic amine (see Scheme 1, 1.5 mmol) dropwise at 0–5°C. The mixture was stirred at room temperature overnight and then concentrated under reduced pressure. The residue was extracted with dichloromethane (2×30 mL). The extract was washed with brine, dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography to produce the pure compounds 9a–e, 10a–e, 11a–e.

Method B A solution of 2-methyl-4-oxo-thieno[2,3-d]pyrimidine-3-carboxylic acid (6–8, 1.0 mmol) in dichloromethane (10 mL) was treated with oxalyl chloride (3 mmol) and the mixture was stirred at room temperature for 3 h. The solvent and the excess of oxalyl chloride were removed under reduced pressure and the residue was treated with an aromatic amine (see Scheme 1, 1.1 mmol) and triethylamine (1.2 mmol). The mixture was stirred at room temperature for 8 h, then washed with water and concentrated under reduced pressure. The residue was purified by silica gel chromatography and eluted with petroleum ether/ethyl acetate to give the pure compounds 9f–q, 10f–q, 11f–q.

N-Butyl-2-methyl-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9a)

Yield 81%; light yellow solid; mp 119–121°C; 1H NMR: δ 10.40 (d, J=3.8 Hz, 1H), 4.23 (t, J=7 Hz, 2H), 3.41 (t, J=7 Hz, 2H), 3.20 (t, J=8 Hz, 2H), 2.87 (s, 3H), 2.38–2.30 (m, 2H), 1.69–1.59 (m, 2H), 1.49–1.39 (m, 2H), 0.96 (t, J=7 Hz, 3H); 13C NMR: δ 163.5, 163.3, 159.2, 158.6, 145.8, 126.3, 118.6, 47.4, 39.5, 32.0, 31.5, 20.4, 19.6, 17.5, 13.9. HRMS (ESI). Calcd for C15H19N3O2S [M–H]: m/z 305.1193. Found: m/z 305.1198.

N-(sec-Butyl)-2-methyl-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9b)

Yield 89%; light yellow solid; mp 113–115°C; 1H NMR: δ 10.21 (d, J=4.3 Hz, 1H), 4.23 (t, J=7 Hz, 2H), 4.09–4.01 (m, 1H), 3.20 (t, J=8 Hz, 2H), 2.86 (s, 3H), 2.38–2.30 (m, 2H), 1.72–1.53 (m, 2H), 1.25 (d, J=7 Hz, 3H), 0.98 (t, J=7 Hz, 3H); 13C NMR: δ 163.4, 162.6, 159.2, 158.5, 145.5, 126.7, 118.6, 46.8, 38.7, 32.0, 29.5, 20.1, 19.6, 17.5, 10.6. HRMS (ESI). Calcd for C15H19N3O2S [M–H]: m/z 305.1192. Found: m/z 305.1198.

N,N-Diisopropyl-2-methyl-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9c)

Yield 82%; white solid; mp 207–209°C; 1H NMR: δ 4.16 (t, J=7 Hz, 2H), 3.79–3.72 (m, 1H), 3.57–3.50 (m, 1H), 3.16 (t, J=8 Hz, 2H), 2.44 (s, 3H), 2.28 (m, 2H), 1.67 (d, J=7 Hz, 3H), 1.58 (d, J=7 Hz, 3H), 1.14 (t, J=7 Hz, 6H); 13C NMR: δ 164.8, 163.6, 159.9, 156.2, 131.5, 130.8, 120.0, 51.2, 46.5, 46.0, 32.2, 21.3, 20.8, 20.2, 19.9, 19.7, 13.7. HRMS (ESI). Calcd for C17H23N3O2S [M–H]: m/z 333.1507. Found: m/z 333.1511.

2-Methyl-N-octyl-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9d)

Yield 76%; white solid; mp 102–104°C; 1H NMR: δ 10.40 (d, J=3.5 Hz, 1H), 4.23 (t, J=7 Hz, 2H), 3.43–3.36 (m, 2H), 3.20 (t, J=8 Hz, 2H), 2.87 (s, 3H), 2.38–2.30 (m, 2H), 1.68–1.61 (m, 2H), 1.43–1.23 (m, 10H), 0.87 (t, J=7 Hz, 3H); 13C NMR: δ 163.5, 163.2, 159.2, 158.6, 145.8, 126.4, 118.6, 47.3, 39.7, 32.0, 31.8, 29.4, 29.3, 29.2, 27.2, 22.7, 19.6, 17.5, 14.1. HRMS (ESI). Calcd for C19H27N3O2S [M–H]: m/z 361.1831. Found: m/z 361.1824.

N-Cyclohexyl-2-methyl-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9e)

Yield 87%; light yellow solid; mp 186–188°C; 1H NMR: δ 10.27 (d, J=7 Hz, 1H), 4.23 (t, J=7 Hz, 2H), 3.98–3.87 (m, 1H), 3.20 (t, J=8 Hz, 2H), 2.86 (s, 3H), 2.38–2.30 (m, 2H), 2.06–1.99 (m, 2H), 1.82–1.73 (m, 2H), 1.58–1.17 (m, 6H); 13C NMR: δ 163.4, 162.3, 159.2, 158.5, 145.6, 126.6, 118.7, 48.5, 47.4, 32.9, 32.0, 25.8, 25.0, 19.6, 17.5. HRMS (ESI). Calcd for C17H21N3O2S [M–H]m/z 331.1348. Found: m/z 331.1354.

2-Methyl-4-oxo-N-(o-tolyl)-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9f)

Yield 87%; white solid; mp 213–215°C; 1H NMR: δ 12.45 (s, 1H), 7.68 (d, J=8 Hz, 1H), 7.25–7.18 (m, 2H), 7.12–7.05 (m, 1H), 4.15 (t, J=7 Hz, 2H), 3.10 (t, J=7 Hz, 2H), 2.89 (s, 3H), 2.42–2.35 (m, 2H), 2.35 (s, 3H); 13C NMR: δ 162.7, 161.7, 159.0, 158.4, 147.1, 135.9, 132.4, 129.4, 126.1, 120.5, 118.7, 45.2, 32.8, 23.6, 19.5, 17.7. HRMS (ESI). Calcd for C18H17N3O2S [M–H]: m/z 339.1049. Found: m/z 339.1041.

2-Methyl-4-oxo-N-(o-tolyl)-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9g)

Yield 79%; white solid; mp 257–259°C; 1H NMR: δ 12.77 (s, 1H), 7.67 (d, J=8 Hz, 2H), 7.14 (d, J=8 Hz, 2H), 4.25 (t, J=7 Hz, 2H), 3.20 (t, J=8 Hz, 2H), 2.93 (s, 3H), 2.39–2.30 (m, 2H), 2.33 (s, 3H); 13C NMR: δ 163.4, 161.0, 159.3, 159.0, 147.5, 136.6, 133.1, 129.3, 126.4, 120.3, 118.2, 47.5, 31.9, 20.9, 19.5, 18.0. HRMS (ESI). Calcd for C18H17N3O2S [M–H]: m/z 339.1048. Found: m/z 339.1041.

N-(4-Methoxyphenyl)-2-methyl-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9h)

Yield 76%; light yellow solid; mp 201–203°C; 1H NMR: δ 12.70 (s, 1H), 7.69 (d, J=9 Hz, 2H), 6.88 (d, J=9 Hz, 2H), 4.24 (t, J=7 Hz, 2H), 3.81 (s, 3H), 3.21 (t, J=8 Hz, 2H), 2.92 (s, 3H), 2.39–2.28 (m, 2H); 13C NMR: δ 163.3, 160.9, 159.4, 158.9, 156.0, 147.4, 132.4, 126.3, 121.8, 118.3, 114.0, 55.5, 47.5, 31.9, 19.5, 17.9. HRMS (ESI). Calcd for C18H17N3O3S [M–H]: m/z 355.0999. Found: m/z 355.0991.

N-(2,6-Dimethylphenyl)-2-methyl-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9i)

Yield 86%; light yellow solid; mp 215–217°C; 1H NMR: δ 12.02 (s, 1H), 7.14–7.07 (m, 3H), 4.24 (t, J=7 Hz, 2H), 3.22 (t, J=8.0 Hz, 2H), 2.91 (s, 3H), 2.39–2.32 (m, 2H), 2.31 (s, 6H); 13C NMR: δ 163.5, 161.5, 159.3, 158.8, 147.5, 135.3, 135.1, 127.9, 126.5, 125.8, 118.6, 47.4, 32.0, 19.6, 18.7, 17.8. HRMS (ESI). Calcd for C19H19N3O2S [M–H]: m/z 353.1191. Found: m/z 353.1198.

N-(4-Acetylphenyl)-2-methyl-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9j)

Yield 89%; light yellow solid; mp 189–191°C; 1H NMR: δ 13.32 (s, 1H), 7.94 (d, J=9 Hz, 2H), 7.88 (d, J=9 Hz, 2H), 4.26 (t, J=7 Hz, 2H), 3.22 (t, J=8 Hz, 2H), 2.94 (s, 3H), 2.58 (s, 3H), 2.41–2.32 (m, 2H); 13C NMR: δ 197.0, 163.5, 161.3, 159.5, 159.0, 148.9, 143.9, 132.2, 129.5, 125.8, 119.4, 118.0, 47.6, 31.9, 26.4, 19.5, 18.1. HRMS (ESI). Calcd for C19H17N3O3S [M–H]: m/z 367.0984. Found: m/z 367.0991.

N-(4-Chlorophenyl)-2-methyl-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9k)

Yield 82%; white solid; mp 252–254°C; 1H NMR: δ 13.05 (s, 1H), 7.79–7.71 (m, 2H), 7.32–7.27 (m, 2H), 4.26 (t, J=7 Hz, 2H), 3.23 (t, J=8 Hz, 2H), 2.93 (s, 3H), 2.41–2.33 (m, 2H); 13C NMR: δ 163.6, 161.1, 159.4, 159.0, 148.3, 137.9, 128.7, 128.4, 126.0, 121.4, 118.1, 47.5, 31.9, 19.6, 18.0. HRMS (ESI). Calcd for C17H14ClN3O2S [M–H]: m/z 359.0486. Found: m/z 359.0495.

N-(2-Chlorophenyl)-2-methyl-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9l)

Yield 84%; light yellow solid; mp 220–222°C; 1H NMR: δ 12.03 (s, 1H), 8.11 (dd, J=8 Hz, 0.9 Hz, 1H), 7.41 (dd, J=8 Hz, 1.3 Hz, 1H), 7.32–7.27 (m, 1H), 7.09 (td, J=8 Hz, 1.5 Hz, 1H), 4.26 (t, J=7 Hz, 2H), 3.22 (t, J=8 Hz, 2H), 2.88 (s, 3H), 2.39–2.31 (m, 2H); 13C NMR: δ 163.3, 161.7, 159.6, 158.3, 147.4, 135.4, 129.5, 127.0, 126.7, 126.0, 125.5, 125.4, 118.5, 47.4, 32.0, 19.6, 17.7. HRMS (ESI). Calcd for C17H14ClN3O2S [M–H]: m/z 359.0483. Found: m/z 359.0495.

N-(4-Bromophenyl)-2-methyl-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9m)

Yield 90%; light yellow solid; mp 224–226°C; 1H NMR: δ 13.06 (s, 1H), 7.71 (d, J=8 Hz, 2H), 7.44 (d, J=8 Hz, 2H), 4.27 (t, J=7 Hz, 2H), 3.23 (t, J=8 Hz, 2H), 2.94 (s, 3H), 2.42–2.32 (m, 2H); 13C NMR: δ 163.6, 161.1, 159.4, 159.1, 148.4, 138.4, 131.7, 126.0, 121.8, 118.1, 116.1, 47.5, 31.9, 19.6, 18.0. HRMS (ESI). Calcd for C17H14BrN3O2S [M–H]: m/z 402.9996. Found: m/z 402.9990.

N-(2,6-Dichlorophenyl)-2-methyl-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9n)

Yield 88%; white solid; mp 267–269°C; 1H NMR: δ 12.27 (s, 1H), 8.09 (d, J=8 Hz, 1H), 7.42 (d, J=2.4 Hz, 1H), 7.29–7.22 (m, 2H), 4.24 (t, J=7 Hz, 2H), 3.23 (t, J=8 Hz, 2H), 2.89 (s, 3H), 2.40–2.31 (m, 2H); 13C NMR: δ 163.4, 161.7, 159.65, 158.5, 148.1, 134.3, 129.9, 129.2, 127.3, 127.2, 126.1, 125.6, 118.4, 47.4, 32.0, 19.6, 17.8. HRMS (ESI). Calcd for C17H13Cl2N3O2S [M–H]: m/z 393.0101. Found: m/z 393.0106.

N-Benzyl-2-methyl-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9o)

Yield 73%; light yellow solid; mp 142–144°C; 1H NMR: δ 10.96 (d, J=1.1 Hz, 1H), 7.40 (d, J=7 Hz, 2H), 7.32 (t, J=7 Hz, 2H), 7.23 (t, J=7 Hz, 1H), 4.63 (d, J=4 Hz, 2H), 4.19 (t, J=7 Hz, 2H), 3.18 (t, J=8 Hz, 2H), 2.88 (s, 3H), 2.36–2.26 (m, 2H); 13C NMR: δ 163.5, 163.3, 159.3, 158.5, 146.4, 139.0, 128.5, 127.7, 126.9, 126.0, 118.6, 47.4, 43.4, 32.0, 19.6, 17.6. HRMS (ESI). Calcd for C18H17N3O2S [M–H]: m/z 339.1035. Found: m/z 339.1041.

2-Methyl-4-oxo-N-(pyridin-2-yl)-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9p)

Yield 76%; light yellow solid; mp 218–220°C; 1H NMR: δ 13.40 (s, 1H), 8.45 (dd, J=5 Hz, 1 Hz, 1H), 8.40 (d, J=8 Hz, 1H), 7.77–7.70 (m, 1H), 7.06–7.01 (m, 1H), 4.33 (t, J=7 Hz, 2H), 3.22 (t, J=8 Hz, 2H), 2.93 (s, 3H), 2.40–2.31 (m, 2H); 13C NMR: δ 163.5, 161.6, 159.7, 158.8, 152.6, 148.4, 147.9, 138.4, 126.0, 119.1, 118.3, 115.0, 47.7, 32.0, 19.6, 17.9. HRMS (ESI). Calcd for C16H14N4O2S [M–H]: m/z 326.0833. Found: m/z 326.0837.

2-Methyl-N-(4-methylpyridin-2-yl)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (9q)

Yield 92%; light yellow solid; mp 166–168°C; 1H NMR: δ 13.32 (s, 1H), 8.21 (d, J=5 Hz, 1H), 8.18 (s, 1H), 6.81 (d, J=5 Hz, 1H), 4.27 (t, J=7 Hz, 2H), 3.16 (t, J=7 Hz, 2H), 2.92 (s, 3H), 2.23–2.11 (m, 2H); 13C NMR: δ 162.3, 161.4, 159.8, 156.2, 152.8, 148.6, 147.8, 146.9, 126.3, 119.7, 118.2, 115.0, 46.3, 31.9, 22.4, 19.1, 18.0. HRMS (ESI). Calcd for C17H16N4O2S [M–H]: m/z 326.0843. Found: m/z 340.0894.

N-Butyl-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10a)

Yield 79%; white solid; mp 209–211°C; 1H NMR: δ 10.40 (d, J=4 Hz, 1H), 4.23 (t, J=7 Hz, 2H), 3.41 (t, J=7 Hz, 2H), 3.20 (t, J=8 Hz, 2H), 2.87 (s, 3H), 2.12–2.06 (m, 2H), 1.97–1.91 (m, 2H)., 1.67–1.57 (m, 2H), 1.48–1.38 (m, 2H), 0.97 (t, J=7.3 Hz, 3H); 13C NMR: δ 163.4, 163.3, 159.2, 158.5, 145.8, 126.3, 118.6, 47.3, 39.4, 31.9, 31.4, 21.2, 20.4, 19.6, 17.5, 13.9. HRMS (ESI). Calcd for C16H21N3O2S [M–H]: m/z 319.1350. Found: m/z 319.1354.

N-(sec-Butyl)-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10b)

Yield 86%; light yellow solid; mp 109–111°C; 1H NMR: δ 10.19 (d, J=6 Hz, 1H), 4.07 (t, J=6 Hz, 2H), 4.08–4.02 (m, 1H), 2.99 (t, J=7 Hz, 2H), 2.86 (s, 3H), 2.06–2.01 (m, 2H), 1.97–1.91 (m, 2H), 1.70–1.56 (m, 2H), 1.25 (d, J=7 Hz, 3H), 0.98 (t, J=7 Hz, 3H); 13C NMR: δ 162.7, 161.6, 159.6, 154.8, 145.1, 126.8, 118.5, 46.7, 43.1, 31.5, 29.5, 22.1, 20.1, 19.0, 17.4, 10.6. HRMS (ESI). Calcd for C16H21N3O2S [M–H]: m/z 319.1350. Found: m/z 319.1354.

N,N-Diisopropyl-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10c)

Yield 89%; light yellow solid; mp 187–189°C; 1H NMR: δ 4.13–4.04 (m, 1H), 3.98–3.91 (m, 1H), 3.79–3.72 (m, 1H), 3.57–3.49 (m, 1H), 2.96 (t, J=6 Hz, 2H), 2.44 (s, 3H), 2.01–1.89 (m, 4H), 1.68 (d, J=7 Hz, 3H), 1.58 (d, J=7 Hz, 3H), 1.13 (dd, J=7 Hz, 4 Hz, 6H); 13C NMR: δ 165.0, 162.1, 157.2, 155.3, 131.2, 130.9, 119.7, 51.2, 45.9, 42.1, 31.6, 22.0, 21.3, 20.8, 20.2, 19.9, 19.2, 13.7. HRMS (ESI). Calcd for C18H25N3O2S [M–H]m/z 347.1661. Found: m/z 347.1667.

2-Methyl-N-octyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10d)

Yield 81%; light yellow solid; mp 103–105°C; 1H NMR: δ 10.42 (s, 1H), 4.06 (t, J=6 Hz, 2H), 3.40 (dd, J=12 Hz, 7 Hz, 2H), 3.00 (t, J=7 Hz, 2H), 2.86 (s, 3H), 2.06–2.02 (m, 2H), 1.98–1.90 (m, 2H), 1.68–1.60 (m, 2H), 1.44–1.25 (m, 10H), 0.88 (t, J=7 Hz, 3H); 13C NMR: δ 163.4, 161.7, 159.6, 154.7, 145.4, 126.5, 118.5, 43.1, 39.7, 31.8, 31.5, 29.4, 29.3, 29.2, 27.2, 22.7, 22.2, 19.0, 17.4, 14.1. HRMS (ESI). Calcd for C20H29N3O2S [M–H]: m/z 375.1986. Found: m/z 375.1980.

N-Cyclohexyl-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10e)

Yield 77%; white solid; mp 195–197°C; 1H NMR: δ 10.23 (d, J=7 Hz, 1H), 4.07 (t, J=6 Hz, 2H), 3.97 –3.90 (m, 1H), 3.00 (t, J=7 Hz, 2H), 2.85 (s, 3H), 2.06 –1.98 (m, 4H), 1.98–1.91 (m, 2H), 1.81–1.74 (m, 2H), 1.48–1.20 (m, 6H); 13C NMR: δ 162.4, 161.4, 159.5, 154.8, 145.2, 126.8, 118.5, 48.4, 43.1, 32.9, 31.4, 25.8, 25.0, 22.1, 19.0, 17.4. HRMS (ESI). Calcd for C18H23N3O2S [M–H]: m/z 345.1517. Found: m/z 345.1511.

2-Methyl-4-oxo-N-(o-tolyl)-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10f)

Yield 80%; light yellow solid; mp 155–157°C; 1H NMR: δ 12.18 (s, 1H), 7.78 (d, J=8 Hz, 1H), 7.25–7.18 (m, 2H), 7.12–7.05 (m, 1H), 4.09 (t, J=6 Hz, 2H), 3.02 (t, J=7 Hz, 2H), 2.91 (s, 3H), 2.38 (s, 3H), 2.07–2.01 (m, 2H), 1.99–1.91 (m, 2H). 13C NMR: δ 161.7, 161.6, 159.8, 154.9, 147.4, 136.6, 131.6, 130.5, 126.2, 126.9, 125.1, 124.9, 118.3, 43.2, 31.5, 22.1, 19.0, 18.5, 17.9. HRMS (ESI). Calcd for C19H19N3O2S [M–H]: m/z 353.1191. Found: m/z 353.1198.

2-Methyl-4-oxo-N-(p-tolyl)-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10g)

Yield 75%; light yellow solid, mp 226–228°C; 1H NMR: δ 12.81 (s, 1H), 7.67 (d, J=8 Hz, 2H), 7.14 (d, J=8 Hz, 2H), 4.09 (t, J=6 Hz, 2H), 3.01 (t, J=7 Hz, 2H), 2.92 (s, 3H), 2.33 (s, 3H), 2.07–2.01 (m, 2H), 1.98–1.90 (m, 2H); 13C NMR: δ 161.6, 161.1, 160.1, 154.9, 147.2, 136.7, 133.1, 129.3, 126.5, 120.3, 118.1, 43.4, 31.5, 22.2, 20.9, 19.0, 17.9. HRMS (ESI). Calcd for C19H19N3O2S [M–H]: m/z 353.1193. Found: m/z 353.1198.

N-(4-Methoxyphenyl)-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10h)

Yield 86%; light yellow solid; mp 201–203°C; 1H NMR: δ 12.74 (s, 1H), 7.70 (d, J=9 Hz, 2H), 6.89 (d, J=9 Hz, 2H), 4.10 (t, J=6 Hz, 2H), 3.81 (s, 3H), 3.03 (t, J=7 Hz, 2H), 2.92 (s, 3H), 2.08–2.02 (m, 2H), 2.00–1.92 (m, 2H); 13C NMR: δ 161.4, 161.0, 160.0, 155.9, 154.9, 147.1, 132.4, 126.4, 121.8, 118.1, 114.0, 55.5, 43.4, 31.4, 22.1, 19.0, 17.8. HRMS (ESI). Calcd for C19H19N3O3S [M–H]: m/z 369.1142. Found: m/z 369.1147.

N-(2,6-Dimethylphenyl)-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10i)

Yield 83%; white solid; mp 186–188°C; 1H NMR: δ 12.11 (s, 1H), 7.12–7.04 (m, 3H), 4.08 (t, J=6 Hz, 2H), 3.03 (t, J=6 Hz, 2H), 2.91 (s, 3H), 2.31 (s, 6H), 2.08–2.01 (m, 2H), 2.00–1.92 (m, 2H); 13C NMR: δ 161.8, 161.6, 159.9, 154.9, 147.3, 135.3, 135.2, 127.9, 126.5, 125.8, 118.4, 43.3, 31.5, 22.1, 19.0, 18.7, 17.7. HRMS (ESI). Calcd for C20H21N3O2S [M–H]: m/z 367.1360. Found: m/z 367.1354.

N-(4-Acetylphenyl)-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10j)

Yield 74%; white solid; mp 230–232°C; 1H NMR: δ 13.35 (s, 1H), 7.95 (d, J=9 Hz, 2H), 7.89 (d, J=9 Hz, 2H), 4.31 (t, J=7 Hz, 2H), 3.25 (t, J=8 Hz, 2H), 2.91 (s, 3H), 2.62 (s, 3H), 2.45–2.37 (m, 2H). 2.05–1.93 (m, 2H); 13C NMR: δ 197.1, 162.1, 160.2, 159.8, 159.6, 149.3, 143.8, 132.3, 129.5, 126.0, 119.5, 118.0, 45.6, 31.7, 26.6, 22.7, 19.3, 18.1. HRMS (ESI). Calcd for C20H19N3O3S [M–H]: m/z 381.1154. Found: m/z 381.1147.

N-(4-Chlorophenyl)-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10k)

Yield 83%; light yellow solid; mp 238–240°C; 1H NMR: δ 13.15 (s, 1H), 7.76 (d, J=9 Hz, 2H), 7.30 (d, J=9 Hz, 2H), 4.12 (t, J=6 Hz, 2H), 3.03 (t, J=6 Hz, 2H), 2.93 (s, 3H), 2.11–2.03 (m, 2H), 2.01–1.93 (m, 2H); 13C NMR: δ 161.8, 161.2, 160.2, 154.9, 148.1, 137.9, 128.7, 128.3, 126.0, 121.4, 117.9, 43.5, 31.5, 22.1, 19.0, 18.0. HRMS (ESI). Calcd for C18H16ClN3O2S [M–H]: m/z 373.0646. Found: m/z 373.0652.

N-(2-Chlorophenyl)-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10l)

Yield 87%; light yellow solid; mp 182–184°C; 1H NMR: δ 12.08 (s, 1H), 8.15 (d, J=8 Hz, 1H), 7.42 (dd, J=8, 1.1 Hz, 1H), 7.34–7.27 (m, 1H), 7.09 (td, J=8 Hz, 1.4 Hz, 1H), 4.11 (t, J=6 Hz, 2H), 3.03 (t, J=6 Hz, 2H), 2.88 (s, 3H), 2.08–2.02 (m, 2H), 1.99–1.92 (m, 2H); 13C NMR: δ 161.8, 161.6, 159.5, 155.1, 147.2, 135.4, 127.1, 126.4, 126.0, 125.4, 125.2, 118.3, 43.2, 31.5, 22.1, 19.0, 17.6. HRMS (ESI). Calcd for C18H16ClN3O2S [M–H]: m/z 373.0645. Found: m/z 373.0652.

N-(4-Bromophenyl)-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10m)

Yield 94%; white solid; mp 234–236°C; 1H NMR: δ 13.16 (s, 1H), 7.70 (d, J=9 Hz, 2H), 7.44 (d, J=9 Hz, 2H), 4.10 (t, J=6 Hz, 2H), 3.03 (t, J=6 Hz, 2H), 2.92 (s, 3H), 2.09–2.03 (m, 2H), 2.01–1.93 (m, 2H); 13C NMR: δ 161.8, 161.2, 160.2, 154.9, 148.1, 138.4, 131.6, 126.0, 121.7, 117.9, 116.0, 77.3, 77.0, 76.7, 43.5, 31.5, 22.1, 19.0, 18.0. HRMS (ESI). Calcd for C18H16BrN3O2S [M–H]: m/z 417.0145. Found: m/z 417.0147.

N-(2,6-Dichlorophenyl)-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10n)

Yield 91%; light yellow solid; mp 165–167°C; 1H NMR: δ 12.26 (s, 1H), 8.14 (d, J=9 Hz, 1H), 7.42 (d, J=2.3 Hz, 1H), 7.29–7.22 (m, 1H), 4.11 (t, J=6 Hz, 2H), 3.03 (t, J=6 Hz, 2H), 2.88 (s, 3H), 2.08–2.01 (m, 2H), 2.00–1.92 (m, 2H); 13C NMR: δ 161.8, 161.4, 159.6, 155.2, 147.9, 134.4, 129.7, 129.2, 127.2, 126.9, 125.8, 125.7, 118.2, 43.3, 31.5, 22.1, 19.0, 17.7. HRMS (ESI). Calcd for C18H15Cl2N3O2S [M–H]: m/z 407.0260. Found: m/z 407.0262.

N-Benzyl-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10o)

Yield 82%; white solid; mp 113–115°C; 1H NMR: δ 10.90 (s, 1H), 7.41 (d, J=7 Hz, 2H), 7.32 (t, J=7 Hz, 2H), 7.24 (t, J=7 Hz, 1H), 4.64 (d, J=5 Hz, 2H), 4.03 (t, J=6 Hz, 2H), 3.00 (t, J=6 Hz, 2H), 2.87 (s, 3H), 2.04–1.97 (m, 2H), 1.97–1.90 (m, 2H); 13C NMR: δ 163.4, 161.4, 159.6, 154.9, 146.0, 139.0, 128.4, 127.7, 126.9, 126.1, 118.4, 43.5, 43.2, 31.4, 22.1, 19.0, 17.5. HRMS (ESI). Calcd for C19H19N3O2S [M–H]: m/z 353.1203. Found: m/z 353.1198.

2-Methyl-4-oxo-N-(pyridin-2-yl)-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10p)

Yield 75%; white solid; mp 181–183°C; 1H NMR: δ 13.29 (s, 1H), 8.31 (dd, J=5 Hz, 1.2 Hz, 1H), 8.27 (d, J=8 Hz, 1H), 7.67–7.59 (m, 1H), 7.11–7.05 (m, 1H), 4.31 (t, J=7 Hz, 2H), 3.13 (t, J=8 Hz, 2H), 2.94 (s, 3H), 2.08–2.04 (m, 2H), 1.97–1.91 (m, 2H); 13C NMR: δ 162.7, 161.9, 159.8, 156.7, 152.4, 149.2, 147.9, 138.9, 126.2, 119.8, 118.6, 115.7, 47.7, 32.0, 19.6, 17.9. HRMS (ESI). Calcd for C17H16N4O2S [M–H]: m/z 340.0988. Found: m/z 340.0994.

2-Methyl-N-(4-methylpyridin-2-yl)-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-3-carboxamide (10q)

Yield 84%; white solid; mp 190–192°C; 1H NMR: δ 13.29 (s, 1H), 8.28 (d, J=5 Hz, 1H), 8.24 (s, 1H), 6.85 (d, J=5 Hz, 1H), 4.19 (t, J=6 Hz, 2H), 3.01 (t, J=6 Hz, 2H), 2.93 (s, 3H), 2.39 (s, 3H), 2.06–1.99 (m, 2H), 1.98–1.91 (m, 2H); 13C NMR: δ 161.7, 161.6, 159.9, 155.2, 152.8, 149.4, 148.0, 147.9, 126.2, 120.4, 118.1, 115.3, 43.4, 31.5, 22.1, 21.4, 19.0, 17.9. HRMS (ESI). Calcd for C18H18N4O2S [M–H]: m/z 354.1154. Found: m/z 354.1150.

N-Butyl-2-methyl-4-oxo-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11a)

Yield 75%; white solid; mp 121–123°C; 1H NMR: δ 10.18 (s, 1H), 4.40 (t, J=4 Hz, 2H), 3.41 (q, J =5 Hz, 2H), 3.07 (t, J=5 Hz, 2H), 2.85 (s, 3H), 1.84 (dd, J=20 Hz, 2.6 Hz, 6H), 1.68–1.59 (m, 2H), 1.49–1.39 (m, 2H), 0.96 (t, J=7 Hz, 3H); 13C NMR: δ 163.4, 161.1, 159.6, 159.2, 145.5, 126.8, 118.5, 43.3, 39.4, 37.1, 31.5, 29.4, 27.4, 25.0, 20.4, 17.3, 13.9. HRMS (ESI). Calcd for C17H23N3O2S [M–H]: m/z 333.1516. Found: m/z 333.1511.

N-(sec-Butyl)-2-methyl-4-oxo-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11b)

Yield 82%; light yellow solid; mp 153–155°C; 1H NMR: δ 9.96 (s, 1H), 4.41 (t, J=4 Hz, 2H), 3.06 (t, J=4 Hz, 2H), 2.84 (s, 3H), 1.87–1.81 (m, 6H), 1.69–1.54 (m, 2H), 1.25 (d, J=7 Hz, 3H), 0.98 (t, J=7 Hz, 3H); 13C NMR: δ 162.8, 161.2, 159.6, 159.2, 145.1, 127.2, 118.6, 46.8, 43.3, 37.1, 29.5, 29.5, 27.5, 25.0, 20.1, 17.3, 10.6. HRMS (ESI). Calcd for C17H23N3O2S [M–H]: m/z 333.1518. Found: m/z 333.1511.

N,N-Diisopropyl-2-methyl-4-oxo-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11c)

Yield 80%; light yellow solid; mp 178–180°C; 1H NMR: δ 4.45 (t, J=4 Hz, 2H), 3.79–3.69 (m, 1H), 3.58–3.48 (m, 1H), 3.06 (t, J=4 Hz, 2H), 2.43 (s, 3H), 1.93–1.70 (m, 6H), 1.68 (d, J=7 Hz, 3H), 1.58 (d, J=7Hz, 3H), 1.13 (t, J=6 Hz, 6H); 13C NMR: δ 164.9, 161.4, 160.2, 156.9, 131.8, 131.2, 119.7, 51.2, 45.9, 42.4, 37.3, 29.6, 27.7, 25.0, 21.2, 20.8, 20.1, 20.0, 13.7. HRMS (ESI). Calcd for C19H27N3O2S [M–H]: m/z 361.1830. Found: m/z 361.1824.

2-Methyl-N-octyl-4-oxo-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11d)

Yield 84%; light yellow solid; mp 102–104°C; 1H NMR: δ 10.18 (s, 1H), 4.40 (t, J=4 Hz, 2H), 3.42–3.37 (m, 2H), 3.06 (t, J=4 Hz, 2H), 2.85 (s, 3H), 1.82–1.78 (m, 6H), 1.68–1.59 (m, 2H), 1.44–1.21 (m, 10H), 0.87 (t, J=6 Hz, 3H); 13C NMR: δ 163.4, 161.4, 159.6, 159.3, 145.5, 126.8, 118.5, 43.3, 39.7, 37.1, 31.8, 29.5, 29.4, 29.3, 29.2, 27.5, 27.2, 25.0, 22.7, 17.4, 14.1. HRMS (ESI). Calcd for C21H31N3O2S [M–H]: m/z 389.2132. Found: m/z 389.2137.

N-Cyclohexyl-2-methyl-4-oxo-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11e)

Yield 76%; light yellow solid; mp 186–188°C; 1H NMR: δ 10.06 (d, J=5 Hz, 1H), 4.41 (t, J=4 Hz, 2H), 3.06 (t, J=4 Hz, 2H), 2.83 (s, 3H), 2.04–2.04 (m, 2H), 1.86–1.76 (m, 8H), 1.65–1.62 (m, 1H), 1.50–1.16 (m, 6H); 13C NMR: δ 162.5, 161.3, 159.6, 159.2, 145.2, 127.1, 118.5, 48.4, 43.2, 37.2, 32.9, 29.5, 27.5, 25.8, 25.0, 25.0, 17.3. HRMS (ESI). Calcd for C19H25N3O2S [M–H]: m/z 359.1663. Found: m/z 359.1667.

2-Methyl-4-oxo-N-(o-tolyl)-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11f)

Yield 86%; light yellow solid; mp 191–193°C; 1H NMR: δ 12.06 (s, 1H), 7.78 (d, J=8 Hz, 1H), 7.22 (dt, J=7 Hz, 4 Hz, 2H), 7.08 (t, J=7 Hz, 1H), 4.48–4.36 (m, 2H), 3.09 (s, 2H), 2.90 (s, 3H), 2.37 (s, 3H), 1.85 (m, 6H); 13C NMR: δ 161.7, 161.3, 159.7, 159.5, 147.5, 136.5, 131.6, 130.4, 126.5, 126.2, 125.1, 124.8, 118.3, 43.4, 37.1, 29.4, 27.4, 25.0, 18.4, 17.8. HRMS (ESI). Calcd for C20H21N3O2S [M–H]: m/z 367.1359. Found: m/z 367.1354.

2-Methyl-4-oxo-N-(p-tolyl)-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11g)

Yield 90%; light yellow solid; mp 223–225°C; 1H NMR: δ 12.71 (s, 1H), 7.67 (d, J=8 Hz, 2H), 7.15 (d, J=8 Hz, 2H), 4.56 (t, J=4 Hz, 2H), 3.09 (d, J=5 Hz, 2H), 2.93 (s, 3H), 2.33 (s, 3H), 1.96–1.61 (m, 6H); 13C NMR: δ 161.4, 161.1, 159.8, 159.7, 147.5, 136.6, 133.1, 129.3, 126.8, 120.3, 118.2, 43.5, 37.1, 29.4, 27.4, 25.0, 20.9, 17.9. HRMS (ESI). Calcd for C20H21N3O2S [M–H]: m/z 367.1360. Found: m/z 367.1354.

N-(4-Methoxyphenyl)-2-methyl-4-oxo-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11h)

Yield 79%; white solid; mp 200–202°C; 1H NMR: δ 12.67 (s, 1H), 7.70 (d, J=9 Hz, 2H), 6.89 (d, J=9 Hz, 2H), 4.56 (t, J=4 Hz, 2H), 3.81 (s, 3H), 3.09 (t, J=5 Hz, 2H), 2.92 (s, 3H), 1.94–1.60 (m, 6H); 13C NMR: δ 161.3, 161.0, 159.8, 159.7, 156.0, 147.4, 132.4, 126.7, 121.9, 118.2, 114.0, 55.5, 43.5, 37.1, 29.4, 27.4, 25.0, 17.9. HRMS (ESI). Calcd for C20H21N3O3S [M–H]: m/z 383.1310. Found: m/z 383.1304.

N-(2,6-Dimethylphenyl)-2-methyl-4-oxo-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11i)

Yield 86%; white solid; mp 199–201°C; 1H NMR: δ 11.93 (s, 1H), 7.12–7.04 (m, 3H), 4.45 (t, J=4 Hz, 2H), 3.12 (t, J=4 Hz, 2H), 2.90 (s, 3H), 2.31 (s, 6H), 1.91–1.82 (m, 6H); 13C NMR: δ 161.6, 161.4, 159.7, 159.6, 147.6, 135.3, 135.2, 127.9, 126.5, 126.1, 118.5, 43.5, 37.1, 29.4, 27.4, 25.0, 18.7, 17.8. HRMS (ESI). Calcd for C21H23N3O2S [M–H]: m/z 381.1506. Found: m/z 381.1511.

N-(4-Acetylphenyl)-2-methyl-4-oxo-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11j)

Yield 88%; light yellow solid; mp 203–205°C; 1H NMR: δ 13.40 (s, 1H), 7.97 (d, J=8 Hz, 2H), 7.90 (d, J=8 Hz, 2H), 4.50 (t, J=4 Hz, 2H), 3.11 (t, J=4 Hz, 2H), 2.95 (s, 3H), 2.59 (s, 3H), 1.92–1.81 (m, 6H); 13C NMR: δ 197.2, 161.6, 161.4, 160.0, 159.8, 149.0, 143.9, 132.2, 129.6, 126.1, 119.4, 118.0, 43.6, 37.2, 29.4, 27.4, 26.4, 25.0, 18.1. HRMS (ESI). Calcd for C21H21N3O3S [M–H]: m/z 395.1300. Found: m/z 395.1304.

N-(4-Chlorophenyl)-2-methyl-4-oxo-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11k)

Yield 82%; light yellow solid; mp 253–255°C; 1H NMR: δ 13.05 (s, 1H), 7.75 (d, J=8 Hz, 2H), 7.30 (d, J=8 Hz, 2H), 4.47 (t, J=5 Hz, 2H), 3.10 (t, J=5 Hz, 2H), 2.92 (s, 3H), 2.01–1.76 (m, 6H); 13C NMR: δ 161.6, 161.2, 160.0, 159.7, 148.3, 137.9, 128.7, 128.4, 126.3, 121.5, 118.0, 43.6, 37.1, 29.4, 27.4, 25.0, 18.0. HRMS (ESI). Calcd for C19H18ClN3O2S [M–H]: m/z 387.0810. Found: m/z 387.0808.

N-(2-Chlorophenyl)-2-methyl-4-oxo-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11l)

Yield 76%; white solid; mp 173–175°C; 1H NMR: δ 13.08 (s, 1H), 8.21 (d, J=8 Hz, 1H), 7.45 (d, J=8, 1H), 7.31–7.24 (m, 1H), 7.12 (t, J=8, Hz, 1H), 4.26 (t, J=6 Hz, 2H), 3.13 (t, J=6 Hz, 2H), 2.93 (s, 3H), 2.08–1.89 (m, 6H); 13C NMR: δ 161.8, 161.6, 159.6, 155.3, 147.2, 135.4, 127.2, 126.5, 126.1, 125.5, 125.2, 118.2, 43.7, 37.1, 29.4, 27.4, 24.9, 18.1. HRMS (ESI). Calcd for C19H18ClN3O2S [M–H]: m/z 387.0812. Found: m/z 387.0808.

N-(4-Bromophenyl)-2-methyl-4-oxo-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11m)

Yield 84%; light yellow solid; mp 263–265°C; 1H NMR: δ 13.08 (s, 1H), 7.71 (d, J=8 Hz, 2H), 7.44 (d, J=8 Hz, 2H), 4.47 (t, J=5 Hz, 2H), 3.10(t, J=5 Hz, 3H), 2.93 (s, 5H), 1.93–1.83 (m, 6H); 13C NMR: δ 161.7, 161.2, 160.0, 159.7, 148.4, 138.4, 131.7, 126.3, 121.8, 118.0, 116.0, 43.6, 37.2, 29.4, 27.4, 25.0, 18.0. HRMS (ESI). Calcd for C19H18BrN3O2S [M–H]: m/z 431.0308. Found: m/z 431.0303.

N-(2,4-Dichlorophenyl)-2-methyl-4-oxo-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11n)

Yield 91%; light yellow solid; mp 201–203°C; 1H NMR: δ 12.11 (s, 1H), 8.16 (d, J=9 Hz, 1H), 7.42 (d, J=4 Hz, 1H), 7.25 (t, J=4 Hz, 1H), 4.46 (t, J=4 Hz, 2H), 3.12–3.05 (t, J=4 Hz, 2H), 2.87 (s, 3H), 1.91–1.79 (m, 6H); 13C NMR: δ 161.6, 161.1, 159.4, 155.2, 147.7, 134.5, 129.7, 129.2, 127.2, 126.8, 125.8, 125.8, 118.2, 43.5, 37.2, 29.3, 27.4, 25.0, 18.1. HRMS (ESI). Calcd for C19H17Cl2N3O2S [M–H]: m/z 421.0423. Found: m/z 421.0419.

N-Benzyl-2-methyl-4-oxo-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11o)

Yield 73%; light yellow solid; mp 116–118°C; 1H NMR: δ 10.76 (s, 1H), 7.41 (d, J=8 Hz, 2H), 7.33 (t, J=8 Hz, 2H), 7.24 (t, J=8 Hz, 1H), 4.64 (d, J=5 Hz, 2H), 4.41–4.34 (t, J=5 Hz, 2H), 3.06 (t, J=5 Hz, 2H), 2.86 (s, 3H), 1.96–1.61 (m, 6H); 13C NMR: δ 163.5, 161.4, 159.6, 159.3, 146.2, 139.0, 128.4, 127.7, 126.9, 126.4, 118.5, 43.4, 43.3, 37.1, 29.4, 27.4, 25.0, 17.5. HRMS (ESI). Calcd for C20H21N3O2S [M–H]: m/z 367.1350. Found: m/z 367.1354.

2-Methyl-4-oxo-N-(pyridin-2-yl)-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11p)

Yield 79%; light yellow solid; mp 212–214°C; 1H NMR: δ 13.29 (s, 1H), 8.44 (d, J=4 Hz, 1H), 8.40 (d, J=8 Hz, 1H), 7.75–7.68 (m, 1H), 7.03 (dd, J=7 Hz, 5 Hz, 1H), 4.53 (t, J=4 Hz, 2H), 3.08 (t, J=4 Hz, 2H), 2.92 (s, 3H), 1.87–1.81 (m, 6H); 13C NMR: δ 161.7, 161.5, 160.0, 159.7, 152.7, 148.3, 148.2, 138.1, 126.3, 119.1, 118.1, 114.9, 43.5, 37.2, 29.5, 27.7, 25.0, 17.9. HRMS (ESI). Calcd for C18H18N4O2S [M–H]: m/z 354.1156. Found: m/z 354.1150.

2-Methyl-N-(4-methylpyridin-2-yl)-4-oxo-4,6,7,8,9,10-hexahydrothieno[2′,3′:4,5]pyrimido[1,2-a]azepine-3-carboxamide (11q)

Yield 74%; light yellow solid; mp 237–239°C; 1H NMR: δ 13.21 (s, 1H), 8.27 (d, J=9 Hz, 2H), 6.86 (d, J=4 Hz, 1H), 4.55 (t, J=4 Hz, 2H), 3.08 (t, J=5 Hz, 2H), 2.92 (s, 3H), 2.39 (s, 3H), 1.86–1.81 (m, 6H); 13C NMR: δ 161.7, 161.5, 160.0, 159.7, 152.7, 149.5, 148.1, 147.9, 126.4, 120.4, 118.2, 115.3, 43.5, 37.2, 29.5, 27.7, 25.0, 21.5, 18.0. HRMS (ESI). Calcd for C19H20N4O2S [M–H]: m/z 368.1315. Found: m/z 368.1307.

Cell culture

Murine B16 melanoma cell lines (B16F10) were obtained from the Chinese Academy of Sciences. The cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (GIBICO, USA) supplemented with 10% heat-inactivated fetal bovine serum (GIBICO, USA), 100 U/mL penicillin and 100 mg/mL streptomycin (GIBCO, USA) in a humidified atmosphere with 5% CO2 at 37°C.

Melanin content assay

Exponentially growing cells were seeded into 6-well plates at a concentration of 5×105 cells per well. After 24 h of incubation at 37°C, the culture medium was removed and replaced with fresh medium containing the candidate compounds at different concentrations. The cells were incubated for another 48 h, washed with ice-cold phosphate-buffered saline (PBS), followed by lysis with radioimmunoprecipitation assay (RIPA) buffer for 40 min on ice, and the lysates were centrifuged at 10 000 g for 20 min. Supernatants containing protein were subjected to protein assay, and the pellets with intracellular melanin were solubilized in 200 μL of 1 m NaOH for 2 h at 60°C. The melanin amount was determined spectrophotometrically at 405 nm using a multi-plate reader. The melanin amount was calculated by normalizing the total melanin values with protein content (abs melanin/L g protein).

Acknowledgments

This work was supported by the National Natural Science Foundation of China, Grant No. 21550110495 and the Chinese Academy of Sciences President’s International Fellowship Initiative (Grant No. 2016PT014).

References

[1] Krüger, C.; Schallreuter, K. U. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int. J. Dermatol.2012, 51, 1206–1212.10.1111/j.1365-4632.2011.05377.xSearch in Google Scholar

[2] Felsten, L. M.; Alikhan, A.; Petronic-Rosic, V. Vitiligo: a comprehensive overview Part II: treatment options and approach to treatment. J. Am. Acad. Dermatol.2011, 65, 493–514.10.1016/j.jaad.2010.10.043Search in Google Scholar

[3] Ezzedine, K.; Eleftheriadou, V.; Whitton, M.; van Geel, N. Vitiligo. Lancet2015, 386, 74–84.10.1016/S0140-6736(14)60763-7Search in Google Scholar

[4] Falabella, R.; Barona, M. I. Update on skin repigmentation therapies in vitiligo. Pigment Cell Melanoma Res.2009, 22, 42–65.10.1111/j.1755-148X.2008.00528.xSearch in Google Scholar PubMed

[5] Nie, L. F.; Bozorov, K.; Niu, C.; Huang, G.; Aisa, H. A. Synthesis and biological evaluation of novel sulfonamide derivatives of tricyclic thieno[2,3-d]pyrimidin-4(3H)-ones on melanin synthesis in murine B16 cells. Res. Chem. Intermed.2017, 43, 6835–6843.10.1007/s11164-017-3023-3Search in Google Scholar

[6] Lerner, A. B.; Denton, C. R.; Fitzpatrick, T. B. Clinical and experimental studies with 8-methoxypsoralen in vitiligo. J. Invest. Dermatol.1953, 20, 299–314.10.1038/jid.1953.36Search in Google Scholar PubMed

[7] Mcneely, W.; Goa, K. L. 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. Drugs1998, 56, 667–690.10.2165/00003495-199856040-00015Search in Google Scholar PubMed

[8] Bleehen, S. S. Treatment of vitiligo with oral 4,5′,8-trimethylpsoralen (trisoralen). Br. J. Dermatol.1972, 86, 54–60.10.1111/j.1365-2133.1972.tb01891.xSearch in Google Scholar PubMed

[9] Pathak, M. A.; Mosher, D. B.; Fitzpatrick, T. B. Safety and therapeutic effectiveness of 8-methoxypsoralen, 4,5′,8-trimethylpsoralen, and psoralen in vitiligo. National Cancer Institute Monograph1984, 66, 165–173.Search in Google Scholar

[10] Whitton, M. E.; Ashcroft, D. M.; Gonzalez, U. Therapeutic interventions for vitiligo. J. Am. Acad. Dermatol.2008, 59, 713–717.10.1016/j.jaad.2008.06.023Search in Google Scholar PubMed

[11] Tippisetty, S.; Goudi, D.; Mohammed, A. W.; Jahan, P. Repair efficiency and PUVA therapeutic response variation in patients with vitiligo. Toxicol. In Vitro2013, 27, 438–440.10.1016/j.tiv.2012.08.003Search in Google Scholar PubMed

[12] Niu, C.; Yin, L.; Nie, L. F.; Dou, J.; Zhao, J. Y.; Li, G.; Aisa, H. A. Synthesis and bioactivity of novel isoxazole chalcone derivatives on tyrosinase and melanin synthesis in murine B16 cells for the treatment of vitiligo. Bioorg. Med. Chem.2016, 24, 5440–5448.10.1016/j.bmc.2016.08.066Search in Google Scholar PubMed

[13] Niu, C.; Pang, G. X.; Li, G.; Dou, J.; Nie, L. F.; Himit, H.; Kabas, M.; Aisa, H. A. Synthesis and biological evaluation of furocoumarin derivatives on melanin synthesis in murine B16 cells for the treatment of vitiligo. Bioorg. Med. Chem.2016, 24, 5960–5968.10.1016/j.bmc.2016.09.056Search in Google Scholar PubMed

[14] Aly, A. A.; Ishak, E. A.; Ramadan, M.; Germoush, M. O.; El-Emary, T. I.; Al-Muaikel, N. S. Recent report on thieno[2,3-d]pyrimidines. Their preparation including microwave and their utilities in fused heterocycles synthesis. J. Heterocycl. Chem.2013, 50, 451–472.10.1002/jhet.1118Search in Google Scholar

[15] Dewal, M. B.; Wani, A. S.; Vidaillac, C.; Oupicky, D.; Rybak, M. J.; Firestine, S. M. Thieno[2,3-d]pyrimidinedione derivatives as antibacterial agents. Eur. J. Med. Chem.2012, 51, 145–153.10.1016/j.ejmech.2012.02.035Search in Google Scholar PubMed PubMed Central

[16] Bozorov, K.; Zhao, J. Y.; Elmuradov, B.; Pataer, A.; Aisa, H. A. Recent developments regarding the use of thieno[2,3-d]pyrimidin-4-one derivatives in medicinal chemistry, with a focus on their synthesis and anticancer properties. Eur. J. Med. Chem.2015, 102, 552–573.10.1016/j.ejmech.2015.08.018Search in Google Scholar PubMed

[17] Narender, M.; Jaswanth, B.; Umashankar, K.; Malathi, J.; Reddy, A. R.; Umadevi, K. R.; Dusthakeer, A. V. N.; Rao, K. V.; Raghuram, A. Synthesis, in vitro antimycobacterial evaluation and docking studies of some new 5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4(3H)-one schiff bases. Bioorg. Med. Chem. Lett.2016, 26, 836–840.10.1016/j.bmcl.2015.12.083Search in Google Scholar PubMed

[18] Narasimhan, B.; Kumari, M.; Jain, N.; Dhake, A.; Sundaravelan, C. Correlation of antibacterial activity of some N-[5-(2-furanyl)-2-methyl-4-oxo-4H-thieno[2,3-d]pyrimidin-3-yl]-carboxamide and 3-substituted-5-(2-furanyl)-2-methyl-3H-thieno[2,3-d]pyrimidin-4-ones with topological indices using Hansch analysis. Bioorg. Med. Chem. Lett.2006, 16, 4951–4958.10.1016/j.bmcl.2006.06.046Search in Google Scholar PubMed

[19] Lilienkampf, A.; Karkola, S.; Alho-Richmond, S.; Koskimies, P.; Johansson, N.; Huhtinen, K.; Vihko, K.; Wähälä, K. Synthesis and biological evaluation of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core. J. Med. Chem.2009, 52, 6660–6671.10.1021/jm900928kSearch in Google Scholar PubMed

[20] Kim, H. J.; Kim, J. S.; Woo, J. T.; Lee, I. S.; Cha, B. Y. Hyperpigmentation mechanism of methyl 3,5-di-caffeoylquinate through activation of p38 and MITF induction of tyrosinase. Acta Biochim. Biophys. Sin.2015, 47, 548–556.10.1093/abbs/gmv040Search in Google Scholar PubMed

Received: 2017-12-11
Accepted: 2017-12-18
Published Online: 2018-01-25
Published in Print: 2018-02-23

©2018 Walter de Gruyter GmbH, Berlin/Boston

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/hc-2017-0256/html
Scroll to top button